WHO Sounds Warning Over Critical Lack of Weight-Loss Medications

Under one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it issues its first recommendations on the therapies.

With more than one billion individuals worldwide currently obese, it is advocating for more widespread and fairer access to GLP-1 medication.

According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.

"The latest guidelines acknowledges that obesity is a chronic disease that can be treated with thorough and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are key barriers to universal access to the jabs that can assist patients in reducing substantial body mass, says the agency.

Skinny Jab Shortage

Even under the current most favorable case, the production of such drugs might only reach about 100 million people – under 10% of the global need, according to the health organization.

The advice encourages nations and manufacturers to expand access, by approaches such as patent sharing.

The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.

How Obesity Injections Work

These medications mimick a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so people consume fewer calories.

People typically see weight reduction after several weeks of commencing the once-weekly jabs.

Evidence indicates people may see weight return after a year of stopping the drug, because their typical hunger return.

To be above a healthy weight increases your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity impacts people in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.